Hepatitis C virus co-infection

Jeffrey J Post1,2, David M Iser3, David A Baker4

Last reviewed: June 2016

Next review due: March 2020

Department of Infectious Diseases and Albion Street Centre,

  1. Prince of Wales Hospital and School of Medical Sciences and Prince of Wales Clinical School, University of New South Wales, Sydney NSW
  2. Infectious Diseases Unit, The Alfred Hospital, and Department of Gastroenterology, St. Vincent’s Hospital, Melbourne VIC
  3. East Sydney Doctors, ASHM

Treatment of hepatitis C virus (HCV) infection is entering a very exciting era of rapid change. New direct acting antiviral (DAA) drugs against HCV have been available in Australia since March 2016. This advance in treatment offers great promise to people living with human immunodeficiency virus (HIV) and HCV co-infection. The significance of HCV co-infection has become apparent since HIV-related mortality has reduced in the era of combination antiretroviral therapy (cART). While the total number of HIV-related deaths has reduced, the proportion of liver-related deaths among people with HIV has increased in cohort studies from around the world.1-4